{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:51:14Z","timestamp":1791251474148,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jash.2016.11.007","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T06:00:57Z","timestamp":1480917657000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient"],"prefix":"10.1016","volume":"11","author":[{"given":"Samuel J.","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9496","key":"10.1016\/j.jash.2016.11.007_bib1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2016.11.007_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2010.07.053","article-title":"Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials","volume":"57","author":"Messerli","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2016.11.007_bib4","doi-asserted-by":"crossref","first-page":"d4891","DOI":"10.1136\/bmj.d4891","article-title":"Management of hypertension: summary of NICE guidance","volume":"343","author":"Krause","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","article-title":"The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"31","author":"Daskalopoulou","year":"2015","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.jash.2016.11.007_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","article-title":"2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"31","year":"2013","journal-title":"J Hypertens"},{"issue":"12","key":"10.1016\/j.jash.2016.11.007_bib7","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1345\/aph.1M381","article-title":"Beta-adrenergic antagonists in hypertension: a review of the evidence","volume":"43","author":"Warmack","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"23","key":"10.1016\/j.jash.2016.11.007_bib8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.279.23.1903","article-title":"Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review","volume":"279","author":"Messerli","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jash.2016.11.007_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"issue":"13","key":"10.1016\/j.jash.2016.11.007_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jacc.2008.05.057","article-title":"Beta-blockers for primary prevention of heart failure in patients with hypertension","volume":"52","author":"Bangalore","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"9246","key":"10.1016\/j.jash.2016.11.007_bib11","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jash.2016.11.007_bib12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028013519591","article-title":"\u03b2-blockers: a review of their pharmacological and physiological diversity in hypertension","volume":"48","author":"Ripley","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"9446","key":"10.1016\/j.jash.2016.11.007_bib13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jash.2016.11.007_bib14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"issue":"9A","key":"10.1016\/j.jash.2016.11.007_bib15","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/j.amjcard.2004.01.020","article-title":"beta-Blockers in hypertension: is carvedilol different?","volume":"93","author":"Messerli","year":"2004","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.jash.2016.11.007_bib16","doi-asserted-by":"crossref","first-page":"60G","DOI":"10.1016\/0002-9149(90)90399-L","article-title":"Beta-blocker duration of action and implications for therapy","volume":"66","author":"Kostis","year":"1990","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","article-title":"Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis","volume":"37","author":"Sharma","year":"2001","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.jash.2016.11.007_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/00044011-200727120-00006","article-title":"Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study","volume":"27","author":"Schmidt","year":"2007","journal-title":"Clin Drug Investig"},{"issue":"11","key":"10.1016\/j.jash.2016.11.007_bib19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1524-6175.2007.07251.x","article-title":"Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial","volume":"9","author":"Wright","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2016.11.007_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/HYPERTENSIONAHA.109.133801","article-title":"Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension","volume":"54","author":"Mackenzie","year":"2009","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jash.2011.12.001","article-title":"Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress","volume":"6","author":"Izzo","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jash.2016.11.007_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.amjhyper.2003.09.012","article-title":"Effect of different antihypertensive drug classes on central aortic pressure","volume":"17","author":"Morgan","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2016.11.007_bib24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/HYPERTENSIONAHA.110.155507","article-title":"Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness","volume":"57","author":"Kampus","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2016.11.007_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","article-title":"A comparison of atenolol and nebivolol in isolated systolic hypertension","volume":"26","author":"Dhakam","year":"2008","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.jash.2016.11.007_bib26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ajh.2008.156","article-title":"Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection","volume":"21","author":"Mahmud","year":"2008","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1016\/j.jash.2016.11.007_bib27","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/HJH.0b013e328364fbca","article-title":"Lack of difference between nebivolol\/hydrochlorothiazide and metoprolol\/hydrochlorothiazide on aortic wave augmentation and central blood pressure","volume":"31","author":"Eeftinck Schattenkerk","year":"2013","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.jash.2016.11.007_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3317\/jraas.2005.022","article-title":"Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters?","volume":"6","author":"Davies","year":"2005","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijcard.2011.10.099","article-title":"Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: The NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study","volume":"155","author":"Vitale","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jash.2016.11.007_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1751-7176.2011.00549.x","article-title":"Carvedilol reduces aortic wave reflection and improves left ventricular\/vascular coupling: a comparison with atenolol (CENTRAL Study)","volume":"13","author":"Shah","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"7","key":"10.1016\/j.jash.2016.11.007_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00003088-200241070-00004","article-title":"Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines","volume":"41","author":"Frishman","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jash.2016.11.007_bib32","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.jash.2016.11.007_bib33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clpt.2004.07.002","article-title":"Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics","volume":"76","author":"Kirchheiner","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2006.02796.x","article-title":"The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension","volume":"63","author":"Lefebvre","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"3\u20134","key":"10.1016\/j.jash.2016.11.007_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s002280050194","article-title":"Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients","volume":"51","author":"Himmelmann","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.jash.2016.11.007_bib36","first-page":"25","article-title":"Clinical pharmacokinetics of nebivolol. A review","volume":"3","author":"Van Peer Snoek","year":"1991","journal-title":"Drug Investig"},{"issue":"9B","key":"10.1016\/j.jash.2016.11.007_bib37","doi-asserted-by":"crossref","first-page":"15J","DOI":"10.1016\/S0002-9149(97)00833-3","article-title":"Clinical relevance of pharmacokinetic differences between beta blockers","volume":"80","author":"Kendall","year":"1997","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jash.2016.11.007_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/clpt.1991.5","article-title":"Population dose versus response of betaxolol and atenolol: a comparison of potency and variability","volume":"49","author":"Sambol","year":"1991","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF00556885","article-title":"Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade","volume":"27","author":"Clague","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jash.2016.11.007_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1751-7176.2011.00515.x","article-title":"\u03b2-Adrenergic blockers","volume":"13","author":"Frishman","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1016\/j.jash.2016.11.007_bib41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/clpt.1982.96","article-title":"Effect of low-dose epinephrine infusion on hemodynamics after selective and nonselective beta-blockade in hypertension","volume":"31","author":"Houben","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"7918","key":"10.1016\/j.jash.2016.11.007_bib42","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(75)92195-9","article-title":"Modification by propranolol of cardiovascular effects of induced hypoglycaemia","volume":"1","author":"Lloyd-Mostyn","year":"1975","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/oxfordjournals.eurheartj.a060160","article-title":"Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise","volume":"13","author":"Lund-Johansen","year":"1992","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jash.2016.11.007_bib44","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jash.2016.11.007_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJM197609092951101","article-title":"Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events","volume":"295","author":"Cryer","year":"1976","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jash.2016.11.007_bib46","first-page":"389P","article-title":"Modification of pressor responses induced by \u201ccold\u201d [proceedings]","volume":"4","author":"Maconochie","year":"1977","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0033-3182(91)72094-X","article-title":"Cardiovascular reactivity to psychosocial stressors. A review of the effects of beta-blockade","volume":"32","author":"Mills","year":"1991","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.jash.2016.11.007_bib48","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/HJH.0b013e32835339ac","article-title":"Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment","volume":"30","author":"Mancia","year":"2012","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","article-title":"Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke","volume":"9","author":"Rothwell","year":"2010","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jash.2016.11.007_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004872-198803000-00001","article-title":"The blood pressure seeking properties of the central nervous system","volume":"6","author":"Julius","year":"1988","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.jash.2016.11.007_bib51","first-page":"453","article-title":"Changes of general haemodynamics during stressful mental arithmetic and non-stressing quiet conversation and modification of the latter by beta-adrenergic blockade","volume":"36","author":"Ulrych","year":"1969","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00003088-199426050-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of carvedilol","volume":"26","author":"Morgan","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00003088-198409020-00003","article-title":"Clinical pharmacokinetics of labetalol","volume":"9","author":"McNeil","year":"1984","journal-title":"Clin Pharmacokinet"},{"issue":"6 Pt 1","key":"10.1016\/j.jash.2016.11.007_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0895-7061(00)01302-9","article-title":"Low-dose alpha\/beta blockade in the treatment of essential hypertension","volume":"14","author":"Mann","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2016.11.007_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0002-8703(91)90864-E","article-title":"The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers","volume":"121","author":"Englert","year":"1991","journal-title":"Am Heart J"},{"issue":"3 Pt 2","key":"10.1016\/j.jash.2016.11.007_bib56","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/0002-8703(91)90813-W","article-title":"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials","volume":"122","author":"Pool","year":"1991","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jash.2016.11.007_bib57","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archinte.1988.00380030045010","article-title":"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension","volume":"148","author":"Holtzman","year":"1988","journal-title":"Arch Intern Med"},{"issue":"1 Suppl","key":"10.1016\/j.jash.2016.11.007_bib58","doi-asserted-by":"crossref","first-page":"75S","DOI":"10.1111\/j.1365-2125.1982.tb01892.x","article-title":"Labetalol steady-state pharmacokinetics in hypertensive patients","volume":"13","author":"McNeil","year":"1982","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 6","key":"10.1016\/j.jash.2016.11.007_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2165\/00003495-198800366-00015","article-title":"Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study","volume":"36","author":"McPhillips","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.jash.2016.11.007_bib60","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/phrs.1998.0387","article-title":"Pharmacology of nebivolol","volume":"38","author":"Mangrella","year":"1998","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jash.2016.11.007_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1527-3466.2008.00044.x","article-title":"Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol","volume":"26","author":"Ignarro","year":"2008","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.jash.2016.11.007_bib62","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-199957040-00011","article-title":"Nebivolol in the management of essential hypertension: a review","volume":"57","author":"McNeely","year":"1999","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib63","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s002280050217","article-title":"Pharmacological properties of nebivolol in man","volume":"51","author":"Van Bortel","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jash.2016.11.007_bib64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1026180325278","article-title":"Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS)","volume":"17","author":"Czuriga","year":"2003","journal-title":"Cardiovasc drugs Ther"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001514","article-title":"Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study","volume":"17","author":"Rosei","year":"2003","journal-title":"J Hum Hypertens"},{"issue":"11","key":"10.1016\/j.jash.2016.11.007_bib66","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","article-title":"The efficacy and tolerability of nebivolol in hypertensive African American patients","volume":"9","author":"Saunders","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1016\/j.jash.2016.11.007_bib67","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/00005344-199306000-00002","article-title":"Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life","volume":"21","author":"Van Bortel","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.jash.2016.11.007_bib68","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00005344-200112003-00006","article-title":"Metabolic effects and safety profile of nebivolol","volume":"38","author":"Pessina","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"10.1016\/j.jash.2016.11.007_bib69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.jhh.1001257","article-title":"Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension","volume":"15","author":"Predel","year":"2001","journal-title":"J Hum Hypertens"},{"issue":"13","key":"10.1016\/j.jash.2016.11.007_bib70","doi-asserted-by":"crossref","first-page":"33F","DOI":"10.1016\/0002-9149(87)90039-7","article-title":"Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug","volume":"59","author":"Frishman","year":"1987","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.jash.2016.11.007_bib71","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM198304213081606","article-title":"Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity","volume":"308","author":"Frishman","year":"1983","journal-title":"N Engl J Med"},{"issue":"2 Pt 2","key":"10.1016\/j.jash.2016.11.007_bib72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/0002-8703(82)90129-6","article-title":"Therapeutic trials of pindolol in hypertension: comparison and combination with other drugs","volume":"104","author":"Fanchamps","year":"1982","journal-title":"Am Heart J"},{"issue":"S2","key":"10.1016\/j.jash.2016.11.007_bib73","doi-asserted-by":"crossref","first-page":"163S","DOI":"10.1111\/j.1365-2125.1979.tb04774.x","article-title":"A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension","volume":"8","author":"McNeil","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"2 Pt 2","key":"10.1016\/j.jash.2016.11.007_bib74","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0002-8703(82)90128-4","article-title":"Antihypertensive effects of pindolol","volume":"104","author":"Gonasun","year":"1982","journal-title":"Am Heart J"},{"issue":"Suppl D","key":"10.1016\/j.jash.2016.11.007_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurheartj\/4.suppl_D.1","article-title":"Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol","volume":"4","author":"Lund-Johansen","year":"1983","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jash.2016.11.007_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0025-7125(16)30786-6","article-title":"Beta-adrenergic blockers","volume":"72","author":"Frishman","year":"1988","journal-title":"Med Clin North Am"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib77","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0895-7061(99)00005-9","article-title":"Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects","volume":"12","author":"Blumenfeld","year":"1999","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.jash.2016.11.007_bib78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9149(73)80043-8","article-title":"Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension","volume":"32","author":"B\u00fchler","year":"1973","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib79","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0002-9149(75)90168-X","article-title":"Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension","volume":"36","author":"B\u00fchler","year":"1975","journal-title":"Am J Cardiol"},{"issue":"2A","key":"10.1016\/j.jash.2016.11.007_bib80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9343(84)80056-X","article-title":"Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients","volume":"77","author":"B\u00fchler","year":"1984","journal-title":"Am J Med"},{"issue":"9169","key":"10.1016\/j.jash.2016.11.007_bib81","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","article-title":"Optimisation of antihypertensive treatment by crossover rotation of four major classes","volume":"353","author":"Dickerson","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jash.2016.11.007_bib82","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004872-200204000-00037","article-title":"Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs","volume":"20","author":"Deary","year":"2002","journal-title":"J Hypertens"},{"issue":"7","key":"10.1016\/j.jash.2016.11.007_bib83","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jash.2015.03.009","article-title":"Ambulatory 24\u2013hour cardiac oxygen consumption and blood pressure\u2013heart rate variability: effects of nebivolol and valsartan alone and in combination","volume":"9","author":"Izzo","year":"2015","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003495-198835050-00001","article-title":"Antihypertensive treatment according to age, plasma renin and race","volume":"35","author":"B\u00fchler","year":"1988","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib85","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00005344-197909000-00001","article-title":"Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol","volume":"1","author":"Lund-Johansen","year":"1979","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"10.1016\/j.jash.2016.11.007_bib86","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/00003495-198836060-00006","article-title":"Current status of beta-blocking drugs in the treatment of anxiety disorders","volume":"36","author":"Tyrer","year":"1988","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jash.2016.11.007_bib87","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9343(82)90592-7","article-title":"Effect of beta blockade and beta stimulation on stage fright","volume":"72","author":"Brantigan","year":"1982","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"10.1016\/j.jash.2016.11.007_bib88","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1111\/j.1365-2125.1982.tb01945.x","article-title":"Elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of pindolol","volume":"13","author":"Dominiak","year":"1982","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1751-7176.2010.00387.x","article-title":"Drug therapy for resistant hypertension: simplifying the approach","volume":"13","author":"Mann","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib90","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1751-7176.2012.00616.x","article-title":"Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study","volume":"14","author":"Sica","year":"2012","journal-title":"J Clin Hypertens"},{"issue":"Suppl 4","key":"10.1016\/j.jash.2016.11.007_bib91","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00005344-198507004-00005","article-title":"Position of calcium antagonists in antihypertensive therapy","volume":"7","author":"B\u00fchler","year":"1985","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10.1016\/j.jash.2016.11.007_bib92","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archinte.163.5.525","article-title":"Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks","volume":"163","author":"Douglas","year":"2003","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.jash.2016.11.007_bib93","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.STR.12.2.200","article-title":"Plasma norepinephrine in stroke","volume":"12","author":"Myers","year":"1981","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.jash.2016.11.007_bib94","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/01.STR.0000163257.66207.2d","article-title":"Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association\/American Stroke Association","volume":"36","author":"Adams","year":"2005","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.jash.2016.11.007_bib95","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1751-7176.2012.00605.x","article-title":"A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study","volume":"14","author":"Mann","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9718","key":"10.1016\/j.jash.2016.11.007_bib96","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","article-title":"Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis","volume":"375","author":"Webb","year":"2010","journal-title":"Lancet"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116305915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171116305915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T06:22:31Z","timestamp":1536214951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171116305915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1933171116305915"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2016.11.007","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2016.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society of Hypertension. All rights reserved.","name":"copyright","label":"Copyright"}]}}